张绪穆教授在Science, Nat. Chem., J. Am. Chem. Soc., Angew. Chem.等学术刊物上发表学术论著400余篇,论文他引>15000多次, 其中单篇论文他引>1700次,H index 72,连续多年入选全球知名出版商Elsevier发布的高被引科学家,入选美国斯坦福大学发布的2020年“全球前2%顶尖科学家”榜单。张绪穆教授2002年获得美国化学会Cope Scholar 奖,是第一位荣获此奖的中国内地出生的科学家。张绪穆教授发展的张烯炔环异构化反应(Zhang enyne cycloisomerization)因其重要性成为以其姓氏命名的人名反应,目前全球仅有少数几位华人有此殊荣。因促成建立中国内地首个以诺贝尔奖得主命名的研究机构—深圳格拉布斯研究院,张绪穆教授获得2016年深圳首届“时代深士”称号。
张绪穆教授长期致力于发展高效、高选择性不对称催化反应,利用自己原创的手性配体工具箱为技术平台,以重大药物合成为产业化突破口,开发有自主知识产权、安全、环保、低成本、高质量的药物绿色合成新工艺。张绪穆教授先后成立了凯瑞斯德(苏州)(Chiral Quest,技术产品)和凯特立斯公司(Catalys,技术平台)。凯瑞斯德成立于2008年,已有20多个年产大于5吨的新工艺路线投入生产,每年生产几百吨医药中间体和原料药,影响全世界数亿患者的用药需求。这些药物包括重磅炸弹药物度洛西汀、雷米普利、西格列汀、度鲁特韦等,每年销售额超过4亿元人民币,目前凯瑞斯德正准备2021年在科创板上市,募集资金6亿元。凯特立斯(深圳)科技有限公司成立于2015年,2018年正式启动项目研发,已取得依折麦布、孟鲁斯特、苯福林、沙库必曲等10多种大品种药物新工艺路线的重大突破。
代表性工作
1. Liu Cao, Yingjun Li, Sidi Yang, Guanguan Li, Qifan Zhou, Jing Sun,Tiefeng Xu, Yang Yang, Ruyan Liao, Yongxia Shi, Yujian Yang, Tiaozhen Zhu, Siyao Huang, Yanxi Ji, Feng Cong, Yinzhu Luo, Yujun Zhu, Hemi Luan, Huan Zhang, Jingdiao Chen, Xue Liu, Renru Luo, Lihong Liu, Ping Wang, Yang Yu, Fan Xing, Bixia Ke, Huanying Zheng, Xiaoling Deng, Wenyong Zhang, Chuwen Lin, Mang Shi, ChunMei Li, Yu Zhang, Lu Zhang, Jun Dai, Hongzhou Lu, Jincun Zhao*, Xumu Zhang*, Deyin Guo*; The adenosine analogue prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants, Science Translational Medicine. (just accepted)
2. L. a. Hu, Y.-Z. Wang, L. Xu, Q. Yin*, X. Zhang*,Highly Enantioselective Synthesis of N-Unprotected Unnatural α-Amino Acid Derivatives by Ruthenium-Catalyzed Direct Asymmetric Reductive Amination, Angew. Chem., Int. Ed. 2022, 61, e202202552.
3. Lin, T. Yang, D. Zhang, Y. Zhou, L. Wu, J. Qiu, G.-Q. Chen*, C.-M. Che*, X. Zhang*,Gold-Catalyzed Desymmetric Lactonization of Alkynylmalonic Acids Enabled by Chiral Bifunctional P,N ligands, Angew. Chem., Int. Ed. 2022, 61, e202201739.
4. Zhang, F.; Zeng, J.; Gao, M.; Wang, L.; Chen, G.-Q.; Lu, Y.; Zhang, X. Concise, scalable and enantioselective total synthesis of prostaglandins, Chem.2021, DOI: 10.1038/s41557-021-00706-1.
5. Li, Y.; Cao, L.; Li, G.; Cong, F.; Li, Y.; Sun, J.; Luo, Y.; Chen, G.; Li, G.; Wang, P.; Xing, F.; Ji, Y.; Zhao, J.; Zhang, Y.; Guo, D.; Zhang, X., Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models, Med. Chem. 2021, DOI: 10.1021/acs.jmedchem.0c01929.
6. Wang, F.; Yang, T.; Wu, T.; Zheng, L.-S.; Yin, C.; Shi, Y.; Ye, X.-Y.; Chen, G.-Q.; Zhang, X., Asymmetric Transfer Hydrogenation of alpha-Substituted-beta-Keto Carbonitriles via Dynamic Kinetic Resolution, Am. Chem. Soc. 2021, 143, 2477-2483.
7. Du, X.; Xiao, Y.; Yang, Y.; Duan, Y.-N.; Li, F.; Hu, Q.; Chung, L. W.; Chen, G.-Q.; Zhang, X., Enantioselective Hydrogenation of tetra-Substituted alpha,beta-Unsaturated Carboxylic Acids Enabled by Cobalt(II) Catalysis: Scope and Mechanistic Insights, Chem., Int. Ed. 2021, DOI: 10.1002/anie.202016705.
8. Yang, T.; Sun, Y.; Wang, H.; Lin, Z.; Wen, J.; Zhang, X., Iridium-Catalyzed Enantioselective Hydrogenation of Oxocarbenium Ions: A Case of Ionic Hydrogenation, Chem. 2020, 59, 6108-6114.
9. Hu, L. A.; Zhang, Y.; Zhang, Q. W.; Yin, Q.; Zhang, X., Ruthenium-Catalyzed Direct Asymmetric Reductive Amination of Diaryl and Sterically Hindered Ketones with Ammonium Salts and H2, Chem. 2020, 59, 5321-5325.
10. Du, X.; Xiao, Y.; Huang, J.-M.; Zhang, Y.; Duan, Y.-N.; Wang, H.; Shi, C.; Chen, G.-Q.; Zhang, X., Cobalt-catalyzed highly enantioselective hydrogenation of α,β-unsaturated carboxylic acids, Commun. 2020, 11, 3239.
11. J. P. Collman*, L. Fu, P. C. Herrmann, and X. Zhang; A Functional Model Related to Cytochrome C Oxidase and its Electrocatalytic Four-Electron Reduction of Dioxygen. Science, 1997, 275, 949.
12. J. P. Collman*, X. Zhang, V. J. Lee, E. Uffelman, and J. I.Brauman; Regioselective and Enatioselective Epoxidation Catalyzed By Metalloporphyrins. Science, 1993, 261, 1404.